-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-2024-surv-rep-update-tables-e1-4.xlsx
January 01, 2024 - E-1. Can. Study Characteristics
Table E-1. Cannabis RCTs study characteristics
PMID Author, Year Study Design Crossover Design Enriched Enrollment Randomized Withdrawal Design Setting Pain Population Pain Condition Prior Cannabis Exposure Age Measure (Mean, Median) Age, Years Female % Race, White % Race, Black % Race…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-e-surv-report-3-nonopioid-pharmacol-chronic-pain.xlsx
October 08, 2025 - NPP
Table E-1. Neuropathic pain study characteristics
Author, Year
Country
Trial Type
Quality Rating Type(s) of Pain Demographics Other Population Characteristics N Randomized
N Analyzed Intervention Duration (Weeks) Funding Source
Hussain, 2021
Pakistan
Placebo-controlled
Fair NPP (DPN) Age, mean: 45
Female: 0%
R…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-2025-surv-rep-update-tables-e1-4.xlsx
January 01, 2025 - E-1. Can. Study Characteristics
Table E-1. Cannabis RCTs study characteristics
PMID Author, Year Study Design Crossover Design Enriched Enrollment Randomized Withdrawal Design Setting Pain Population Pain Condition Prior Cannabis Exposure Age Measure (Mean, Median) Age, Years Female % Race, White % Race, Black % Race…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-270-bimp-disposition-comments.pdf
September 18, 2024 - Evidence-based Practice Center Systematic Review Protocol
Comparative Effectiveness Review Disposition of Comments Report
Title: Behavioral Interventions for Migraine Prevention
Draft report available for public comment from September 5, 2023, to October 20, 2023.
Citation: Treadwell…
-
effectivehealthcare.ahrq.gov/sites/default/files/estimation-and-reporting_chapter-3.pptx
January 01, 2013 - analysis)
To predict whether an individual might benefit from a treatment (predictive learning)
Goals for Analyzing … Heterogeneity of
Treatment Effect
Goals for Analyzing Heterogeneity of Treatment Effect
Analyses
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/search-strategy-white-paper.pdf
February 01, 2025 - While not useful for analyzing an existing search per se, it does provide some context of drugs,
topics
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-opioid-chronic-pain-surveillance-report-2.xlsx
September 30, 2015 - Appendix Table D-1. RCTs
Table D-1. Randomized controlled trials
Author, Year Study Design
Duration Setting
Country Eligibility Criteria Interventions Sample Characteristics Screened
Eligible
Randomized
Analyzed Results Adverse Events and Withdrawals Due to Adverse Events Sponsor Quality
Hruschak, 2021 RCT
Duration:…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-opioid-chronic-pain-surveill-report-1.xlsx
September 30, 2015 - Appendix Table D-1. RCTs
Table D-1. Randomized controlled trials
Author, Year Study Design
Duration Setting
Country Eligibility Criteria Interventions Sample Characteristics Screened
Eligible
Randomized
Analyzed Results Adverse Events and Withdrawals Due to Adverse Events Sponsor Quality
Hruschak, 2021 RCT
Duration:…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cancer-anemia-update_executive.pdf
April 01, 2013 - 1
Epoetin and Darbepoetin for Managing
Anemia in Patients Undergoing Cancer
Treatment: Comparative Effectiveness Update
Executive Summary
Background
Anemia, a deficiency in the concentration
of hemoglobin-containing red blood
cells, is prevalent among cancer patients,
depending on the type of malignancy
and t…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/glaucoma-screening-apendices-11-5-10.pdf
December 23, 2009 - Appendix A2: FDA status of medical devices for glaucoma screening
APPENDIX A FDA STATUS- SCREENING DEVICES
SE: Substantially equivalent; Premarket notification, 501(k)
Page 1 of 19
Ophthalmoscope, AC-powered
Product code: HLI
COMPANY PRODUCT FDA STATUS* APPROVAL DATE
ACCUTECH MEDICAL TECHNOLOGIES IN…
-
effectivehealthcare.ahrq.gov/sites/default/files/glaucoma_screening-apendices-11-5-10.pdf
December 23, 2009 - Appendix A2: FDA status of medical devices for glaucoma screening
APPENDIX A FDA STATUS- SCREENING DEVICES
SE: Substantially equivalent; Premarket notification, 501(k)
Page 1 of 19
Ophthalmoscope, AC-powered
Product code: HLI
COMPANY PRODUCT FDA STATUS* APPROVAL DATE
ACCUTECH MEDICAL TECHNOLOGIES IN…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-opioid-chronic-pain-surveillance-report-3.xlsx
September 30, 2015 - Appendix Table D-1. RCTs
Table D-1. Randomized controlled trials
Author, Year Study Design
Duration Setting
Country Eligibility Criteria Interventions Sample Characteristics Screened
Eligible
Randomized
Analyzed Results Adverse Events and Withdrawals Due to Adverse Events Sponsor Quality
Hruschak, 2021 RCT
Duration:…
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-results-search-strategies-developed-with-without-text-mining-tools.pdf
March 01, 2021 - set and comparator set,
development of the search strategy with references from the development set (analyzing
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-surv-report-3-noninvasive-nonpharma_0.xlsx
January 01, 2022 - Title
Appendix D. Evidence Table
Table D-1. Evidence Table
Table D-1. Evidence table for new trials included in surveillance reports for noninvasive nonpharmacological treatment for chronic pain report
Author, Year
Country
Number of Centers and Setting Inclusion/Exclusion Criteria Number …
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-surv-report-2-noninvasive-nonpharma.xlsx
January 01, 2021 - Title
Appendix D. Evidence Table
Table D-1. Evidence Table
Table D-1. Evidence table for new trials included in Surveillance Report 1 for noninvasive nonpharmacological treatment for chronic pain report
Author, Year
Country
Number of Centers and Setting Inclusion/Exclusion Criteria Number…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-surv-report-1-noninvasive-nonpharma_0.xlsx
January 01, 2021 - Title
Appendix D. Evidence Table
Table D-1. Evidence Table
Table D-1. Evidence table for new trials included in Surveillance Report 1 for noninvasive nonpharmacological treatment for chronic pain report
Author, Year
Country
Number of Centers and Setting Inclusion/Exclusion Criteria Number…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/gastric-cancers-protocol.pdf
January 01, 2024 - how treatment effects vary by cancer and demographic subgroups for KQs 2 and 3, we
will prioritize analyzing … multiple
studies evaluating similar comparisons and subgroups report this data, we will consider meta-
analyzing … Key Informants are not involved in
analyzing the evidence or writing the report.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/gastric-cancers-protocol-amended.pdf
February 07, 2025 - how treatment effects vary by cancer and demographic subgroups for KQs 2 and 3, we
will prioritize analyzing … multiple
studies evaluating similar comparisons and subgroups report this data, we will consider meta-
analyzing … Key Informants are not involved in
analyzing the evidence or writing the report.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-g-surv-report-1-nonopioid-pharmacol-chronic-pain.xlsx
October 08, 2025 - RCTs
Table G-1. Quality assessments of included randomized controlled trials
Author, Year Randomization Adequate Allocation Concealment Adequate Patients and Personnel Masked Outcome Assessors Masked Groups Similar at Baseline Intent-to-Treat Analysis (at Least 95% Analyzed) Attrition <20%; Difference Between Groups …
-
effectivehealthcare.ahrq.gov/sites/default/files/diabetic-neuropathy-disposition-170707.pdf
March 24, 2017 - When analyzing newer studies to
add to the analysis of Griebeler et al, it appears that
these newer … We are no longer
analyzing anticonvulsants together as a drug
class, but are only analyzing comparison